PET imaging of multidrug resistance in tumors using 18F-Fluoropaclitaxel

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1792-1798

  Kurdziel, Karen A ^a   Kiesewetter, Dale O ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Drug development; F 18 fluoropaclitaxel; Molecular imaging; Multidrug resistance; Paclitaxel; PET; Pgp

Indexed keywords

BROMINE 76; CARBON 11; DOCETAXEL; FLUORINE 18; FLUOROPACLITAXEL F 18; GLYCOPROTEIN P; IODINE 124; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; SOLID TUMOR; TUMOR RESISTANCE;

DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY;

EID: 77957993299     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928077     Document Type: Article

References (39)

1. Gottesman, M.M. How cancer-cells evade chemotherapy - 16th richard-and-hindarosenthal-foundation award lecture. Cancer Res., 1993, 53, 747-754.
2. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
3. Gottesman, M.M.; Pastan, I.; Ambudkar, S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev., 1996, 6, 610-617.
4. Pavelic, Z.P.; Reising, J.; Pavelic, L.; Kelley, D.J.; Stambrook, P.J.; Gluckman, J.L. Detection of P-Glycoprotein with 4 monoclonal-antibodies in normal and tumor-tissues. Arch. Otolaryngol. Head Neck Surg., 1993, 119, 753-757.
5. Lum, B.; Gosland, M. MDR expression in normal-tissues - pharma-cological implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am., 1995, 9, 319-336.
6. Fox, E.; Bates, S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Exp. Rev. Anticancer Ther., 2007, 7, 447-459.
7. Relling, M.V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monit., 1996, 18, 350-356.
8. Kang, M.H.; Figg, W.D.; Ando, Y.; Blagosklonny, M.V.; Liewehr, D.; Fojo, T.; Bates, S.E. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res., 2001, 7, 1610-1617.
9. Abraham, J.; Edgerly, M.; Wilson, R.; Chen, C.; Rutt, A.; Bakke, S.; Robey, R.; Dwyer, A.; Goldspiel, B.; Balis, F.; Van Tellingen, O.; Bates, S.E.; Fojo, T. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res., 2009, 15, 3574-3582.
10. Society of Nuclear Medicine website (http://www.molecularimag-ingcenter.org/index.cfm?PageID=6324&RPID=7165). 2009, Vol. 2009.
11. Hendrikse, N.H.; Franssen, E.J.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. Visualization of multidrug resistance in vivo. Eur. J. Nucl. Med., 1999, 26, 283-293.
12. Cardarelli, C.O.; Aksentijevich, I.; Pastan, I.; Gottesman, M.M. Differential-effects of p-glycoprotein inhibitors on Nih3t3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res., 1995, 55, 1086-1091.
13. Germann, U.A.; Chambers, T.C.; Ambudkar, S.V.; Licht, T.; Cardarelli, C.O.; Pastan, I. Gottesman, M.M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem., 1996, 271, 1708-1716.
14. Sparreboom, A.; van Tellingen, O.; Nooijen, W.J.; Beijnen, J.H. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs, 1998, 9, 1-17.
15. Huang, Y.; Ibrado, A.M.; Reed, J.C.; Bullock, G.; Ray, S.; Tang, C. Bhalla, K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia, 1997, 11, 253-257.
16. Li, C.; Yu, D.; Inoue, T.; Yang, D.; Tansey, W.; Liu, C.; Milas, L.; Hunter, N.; Kim, E., Wallace, S. Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors. J. Nucl. Med., 1997, 38, 1042-1047.
17. Inoue, T.; Li, C.; Yang, D.J.; Higuchi, T.; Oriuchi, N.; Yu, D.F.; Milas, L.; Hunter, N.; Wallace, S.; Kim, E.E.; Podoloff, D.A. Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel. Ann. Nucl. Med., 1999, 13, 169-174.
18. Watanabe, N.; Oriuchi, N.; Endo, K.; Inoue, T.; Tanada, S.; Murata, H.; Kim, E.E.; Sasaki, Y. Localization of indium-111 in human malignant tumor xenografts and control by chelators. Nucl. Med. Biol., 1999, 26, 853-858.
19. Ravert, H.T.; Klecker, R.W.; Collins, J.M.; Mathews, W.B.; Pomper, M.G.; Wahl, R.L.; Dannals, R.F. Radiosynthesis of [C-11]paclitaxel. J. Labelled Comp. Radiopharm., 2002, 45, 471-477.
20. van Tilburg, E.W.; Mooijer, M.P.J.; Brinkhorst, J.; van der Meij, M.; Windhorst, A.D. Improved and semi-automated GMP-compliant radiosynthesis of [C-11]docetaxel. Appl. Radiat. Isot., 2008, 66, 1414-1418.
21. van Tilburg, E.W.; Franssen, E.J.F.; van der Hoeven, J.J.M.; van der Meij, M.; Elshove, D.; Lammertsma, A.A.; Windhorst, A.D. Radiosynthesis of [C-11]docetaxel. J. Labelled Comp. Radiopharm., 2004, 47, 763-777.
22. Kiesewetter, D.O.; Jagoda, E.M.; Kao, C.H.; Ma, Y.; Ravasi, L.; Shimoji, K.; Szajek, L.P.; Eckelman, W.C. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl. Med. Biol., 2003, 30, 11-24.
23. Georg, G.I.; Boge, T.C.; Cheruvallath, Z.S.; Harriman, G.C.B.; Hepperle, M.; Park, H.; Himes, R.H. Topliss approach to the synthesis of biologically-active substituted n-benzoyl taxol analogs. Bioorg. Med. Chem. Lett., 1994, 4, 1825-1830.
24. Preparation of Taxol and docetaxel through primary amines. Hauser Inc., Boulder, CO., USA, 1996, p. 85.
25. Haka, M.S.; Kilbourn, M.R.; Watkins, G.L.; Toorongian, S.A. Aryl-trimethylammonium Trifluoromethanesulfonates as precursors to aryl F-18 FLuorides - improved synthesis of F-18 GBR-13119. J. Labelled Comp. Radiopharm., 1989, 27, 823-833.
26. Lang, L.; Jagoda, E.; Schmall, B.; Vuong, B.K.; Adams, H.R.; Nelson, D.L.; Carson, R.E.; Eckelman, W.C. Development of fluorine-18-labeled 5-HT1A antagonists. J. Med. Chem., 1999, 42, 1576-1586.
27. Kurdziel, K.; Kiesewetter, D.O.; Carson, R.E.; Eckelman, W.C.; Herscovitch, P. Biodistribution, radiation dose estimates, and in vivo pgp modulation studies of (18)F-Paclitaxel in nonhuman primates. J. Nucl. Med., 2003, 44, 1330-1339.
28. Gangloff, A.; Hsueh, W.A.; Kesner, A.L.; Kiesewetter, D.O.; Pio, B.S.; Pegram, M.D.; Beryt, M.; Townsend, A.; Czernin, J.; Phelps, M.E.; Silverman, D.H. Estimation of paclitaxel biodis-tribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J. Nucl. Med., 2005, 46, 1866-1871.
29. Kalen, J.D.; Hirsch, J.I.; Kurdziel, K.A.; Eckelman, W.C.; Kiesewetter, D.O. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC). Appl. Radiat. Isot., 2007, 65, 696-700.
30. Shen, D.W.; Cardarelli, C.; Hwang, J.; Cornwell, M.; Richert, N.; Ishii, S.; Pastan, I.; Gottesman, M.M. Multiple drug-resistant human kb carcinoma-cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem., 1986, 261, 7762-7770.
31. Kurdziel, K.A.; Kalen, J.D.; Hirsch, J.I.; Wilson, J.D.; Agarwal, R.; Barrett, D.; Bear, H.D.; McCumiskey, J.F. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl. Med. Biol., 2007, 34, 823-831.
32. Dangerfield, W.; Mistry, P.; Stewart, A.J.; Bootle, D.; Liddle, C.; Okiji, S. XR9576, a novel potent modulator of P-glycoprotein-mediated multidrug resistance. Br. J. Cancer, 1998, 78, P43.
33. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol., 1999, 128, 403-411.
34. Lavie, Y.; Cao, H.; Volner, A.; Lucci, A.; Han, T.Y.; Geffen, V.; Giuliano, A.E.; Cabot, M.C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem., 1997, 272, 1682-1687.
35. Hsueh, W.; Kesner, A.; Gangloff, A.; Pegram, M.; Beryt, M.; Czernin, J.; Phelps, M.; Silverman, D. Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J. Nucl. Med., 2006, 47, 1995-1999.
36. Mimnaugh, E.G.; Fairchild, C.R.; Fruehauf, J.P.; Sinha, B.K. Biochemical and pharmacological characterization of MCF-7 drugsensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem. Pharmacol., 1991, 42, 391-402.
37. Fornari, F.A.; Randolph, J.K.; Yalowich, J.C.; Ritke, M.K.; Gewirtz, D.A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol., 1994, 45, 649-656.
38. Logan, J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol., 2000, 27, 661-670.
39. Forrest, M.L.; Yanez, J.A.; Remsberg, C.M.; Ohgami, Y.; Kwon, G.S.; Davies, N.M. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm. Res., 2008, 25, 194-206.